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Abstract
Johne's disease is chronic inflammation of the intestine caused by Mycobacterium avium subspecies
paratuberculosis. Infection and disease are mainly in domestic livestock but can affect many species
including primates. Johne's is a new disease which emerged at the turn of the 19th and 20th centuries
and principally involved Europe and North America. It has since spread to former low incidence
regions to become a global problem. Crohn's disease is a chronic inflammation of the intestine in
humans which emerged in Europe and North America mid 20th century and increased to become
a major healthcare problem. It has now spread to former low incidence regions. Infected animals
shed Mycobacterium avium subspecies paratuberculosis in milk and into the environment. Human
populations are widely exposed. Outcomes maybe influenced by microbial phenotype. Exposure to
extracellular forms of these pathogens may confer some natural protection; exposure to
intracellular forms which have passaged through milk macrophages or environmental protists may
pose a greater threat to humans particularly individuals with an inherited or acquired susceptibility.
Hot spots of human disease such as in Winnipeg which sits on rock at the junction of two rivers
may result from local exposure to high levels of waterborne pathogens brought down from
farmland. When appropriate methods are used most people with Crohn's disease are found to be
infected. There are no data which demonstrate that these pathogens are harmless to humans. An
overwhelming balance of probability and Public health risk favours the conclusion that
Mycobacterium avium subspecies paratuberculosis is also pathogenic for people. A two tier co-
operative pathogenic mechanism is proposed in Crohn's disease. Intracellular infection with the
primary pathogen widely distributed throughout the gut causes an immune dysregulation and a
specific chronic enteric neuropathy with loss of mucosal integrity. Segments of gross inflammatory
disease result from the perturbed neuroimmune response to penetration into the gut wall of
secondary pathogens from the lumen. These include both normal gut organisms and educated
members of the enteric microbiome such as more aggressive E. coli. More new diseases may arise
from failure to apply a range of remedial measures to this longstanding zoonotic problem.
Review
MAP and the emergence of Johne's and Crohn's diseases
Johne's disease (JD) is a systemic infection and chronic
inflammation of the intestine in animals caused by Myco-
bacterium avium subspecies  paratuberculosis  (MAP). It is
most common in ruminants but can affect many other
species including primates. It was first seen to emerge in
Europe and North America at the end of the 19th and
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beginning of the 20th centuries. Crohn's disease (CD) in
humans is a systemic disorder whose principal clinico-
pathological manifestation is also chronic inflammation
of the intestine. It is also a new disease which was first
seen to emerge in the same continents 40–50 years after
JD and increased in frequency steadily until it has become
a major healthcare problem. In some areas in the USA in
recent years the incidence of CD has seemed to plateau
around 7–8 per 105 population per year [1,2]. In Europe
the incidence of CD in adults continues to grow [3-5].
Studies in Stockholm, Czech Republic, and Australia sup-
ported by data from Finland suggest that the incidence of
CD in children in these areas in recent years has been ris-
ing in some cases as high as about 5 fold per decade [6-9].
These rapid changes in incidence rule out a primary
genetic causation of CD. The data from recent genome
wide scans which has identified 32 significant genomic
loci related to susceptibility to CD are consistent with the
involvement of intracellular bacterial pathogens includ-
ing mycobacteria, in disease causation [10].
The rising incidence of CD reported from several former
low incidence countries in Asia shows that, as with JD, CD
is spreading worldwide [11,12]. Recent work from New
Zealand reported a high incidence of CD of 16.5 per 105
per year affecting the Canterbury region of South Island
with Christchurch as its principal city [13]. Mountains are
to the northwest and rivers from them run across rich agri-
cultural pastures and either side of Christchurch before
entering the sea. A small river meanders through the city
itself. Some of these features are reminiscent of the situa-
tion in Cardiff, South Wales UK where a high incidence of
CD in city wards bordering the river Taff draining the
upland pastures of the Brecons and running through the
city was consistent with exposure of the local population
to aerosols from the river [14].
A conspicuously anomalous distribution in the incidence
of CD exists in North America either side of the Canadian
border between Minnesota and Manitoba. In Minnesota
to the south the well documented population-based inci-
dence of CD in Olmsted County is 7.9 per 105/year [1]
whereas in some areas of the city of Winnipeg little more
than 400 miles to the north the incidence reaches a maxi-
mum 3.5 fold greater at 28.07 per 105/year [15]. Winni-
peg lies astride the junction of the Red River of the North
running up from the south and the Assiniboine River
coming in from the west. The city sits on bedrock which
was once the floor of the immense prehistoric glacial lake
Agassiz, with scant run-off in permeable sand and gravel
aquifers [16]. The 'hot spot' of CD in the city of Winnipeg
we see now is probably due to local exposure of the
human population to high levels of waterborne MAP
brought down from the agricultural river catchments of
the US Midwest, meeting those from the provinces of
Manitoba, Saskatchewan and Alberta. Waterborne MAP
under these conditions would almost certainly include
organisms which have adopted the intracellular pheno-
type having been taken up by abundant environmental
protists [17].
Movement of people and pathogen
Migrant studies show that the incidence of CD in people
moving from a low CD and JD incidence area to a high
incidence area subsequently rises to that of the host pop-
ulation. The inverse situation is that in which MAP is
introduced into an isolated community usually by impor-
tation of infected animals. This happened in Iceland in
1933 [reviewed in [18]]. After a latent period following
introduction of the pathogen there were at intervals suc-
cessive epidemics of JD in the island sheep, then in the
cattle, then CD in the human population. From 1960 to a
peak in 1992 the incidence of CD increased 18 fold. Thus
in either case, if people move in amongst MAP or if MAP
is moved in amongst people the result is the same namely
a steep rise in the incidence of CD. The time interval
between the emergence and rise of JD in animals and CD
in humans in Iceland was again about 40–50 years. With
the almost unlimited opportunity for MAP to spread and
evolve in intensively farmed domestic livestock and asso-
ciated contaminated environments over more than a half
century, an evolving virulence and species adaptation of
the pathogen would be reflected in the JD to CD interval
becoming shorter. A recent example of this happening
maybe the steep 4.5 fold increase in CD in the Czech
Republic 1995–2007 following the rise in JD caused by
the unimpeded importation of subclinically infected cat-
tle from Western Europe after independence in 1990.
Natural Immunity to MAP from environmental and 
occupational exposure
Why don't dairy farmers and veterinarians exposed to
MAP-infected animals get a much higher incidence of CD?
Data from the US show that these occupations are in fact
associated with a significantly reduced death rate from
Inflammatory Bowel Disease [19]. Children exposed to
farm animals, particularly cattle, in early life also subse-
quently have a lower incidence of CD [20]. Occupational
exposure to MAP is associated with raised antibody levels
to MAP lysates [21]. An answer to the question consistent
with these observations is that the extracellular classical
ZN-positive phenotype of MAP excreted in trillions by
heavily infected animals is not one to which humans are
most susceptible. Exposure to this form of the organism
may result in the acquisition of some natural immunity to
disease. A good example of this happening as a result of
purposeful exposure is the approximate 10 fold reduction
in clinical Johne's disease achieved subsequently by vacci-
nation of calves using conventional whole killed MAP
vaccines with the organisms in this form [22]. The wellGut Pathogens 2009, 1:15 http://www.gutpathogens.com/content/1/1/15
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described urban preponderance of CD may not be that
townsfolk have an increased susceptibility to CD, rather
that country folk have some natural protection. Passage of
MAP through bovine macrophages in milk and cheese or
through environmental protists would result in a switch
to an intracellular phenotype of MAP likely to have an
enhanced virulence for humans [23,24].
MAP and the convergence of candidate pathogens
With the new 21st century, a steadily increasing volume of
parallel research has identified three principal sets of bac-
teria as candidates for the causation of the gross inflam-
matory disease of the intestine in CD. These are the
community of normal gut flora [25], abnormal gut flora
such as adherent invasive E. coli (AIEC) [26], and MAP.
Because of the global advance of CD and the serious
implications for Public Health as well as cumulative indi-
vidual suffering, there is a need for researchers and clini-
cians in the field to recognise that the reliable evidence
obtained from each of the three lines of inquiry is conver-
gent and that there is actually no conflict between them.
From experimental as well as clinical evidence there is no
doubt that bacteria from the normal intestinal microbial
community can infect and inflame the gut wall and that
they do so in CD. However, the spontaneous emergence
and rise of CD in human populations across the globe due
to an epidemic of normal gut flora, in the absence of
another specific initiating cause, seems rather improba-
ble. The enteric microbiome is a fertile environment for
horizontal gene transfer [27]. Advancement of patho-
genicity in bacteria may follow the acquisition and muta-
tion of genes and changes in their regulation [28-30]. We
already have examples of the pathological consequences
of such adaptation in common gut bacteria such as E. coli
which can be enteropathogenic, enterohaemorrhagic,
enterotoxigenic, enteroaggregative and recently enteroad-
herent and invasive AIEC [31]. Such adaptations usually
arise due to the imposition of some external selection
pressure. Recent evidence also suggests that common
enteric bacteria like E. coli may display predictive behav-
iour [32].
The principal property of MAP which distinguishes it from
all other candidate pathogens in the primary causation of
CD is that it is an established multi-host chronic enteric
pathogen. MAP has the proven specific ability to initiate
and maintain chronic inflammation of the intestine of a
range of different histopathological types in many species
including primates. MAP infection in animals causes a
local and systemic immune dysregulation. It is also specif-
ically neuropathogenic especially for non-myelinated
neurones and intestinal disease is accompanied by a
chronic enteric neuropathy [33]. Despite its broad patho-
genicity, MAP infection can persist in animals for years
without necessarily progressing to clinical disease. Clini-
cal disease in animals when it occurs is commonly of the
pluribacillary type but paucimicrobial disease with the
pathogens in a Ziehl Neelsen (ZN)-negative phenotype is
well described.
The overall prevalence of MAP infection in US dairy herds
is reported by a USDA survey to be 68.1% [34]. A range of
broadly similar data shows that MAP infection in farm
animals is widespread in many areas of Western Europe
and elsewhere. MAP contaminates and persists in water
and the environment, is in dairy products, can survive
milk pasteurisation, and is present in meat from infected
animals. It is inevitable that human populations are
widely exposed.
MAP in humans
MAP infection in humans is difficult to detect. The organ-
isms are present in low abundance in a robust ZN-nega-
tive phenotype. They are intracellular and minimise their
own immune recognition. They are extremely difficult to
isolate and propagate in culture and are relatively resistant
to chemical and enzymatic lysis. Reliable access to their
DNA is only achieved during sample processing by com-
bining exposure to stringent lysis buffers with an addi-
tional optimised mechanical disruption step. Freezing
samples and tissue extracts especially at -20°C substan-
tially reduces the PCR detection rate of their GC-rich
DNA. The organisms have been cultured and detected in
blood showing that, as in animals, the infection in
humans is systemic [35-37]. At present, the benchmark
diagnostic test for MAP infection in humans is nested PCR
applied to single ~20 mg fresh endoscopic mucosal biop-
sies [38]. When validated methodologies have been used
most people with CD have been found to be infected with
MAP [39]. In simple words, most people with chronic
inflammation of the intestine (of the CD type) are
infected with a mycobacterium which is a proven specific
cause of chronic inflammation of the intestine. There are
no data which demonstrate that MAP are harmless to
humans. The overwhelming balance of probability and
public health risk favours the conclusion that MAP are
also pathogenic for people.
Inflammation in Crohn's disease caused by a two tier co-
operative pathogenic mechanism
MAP infects the gut widely in CD and is found both in the
more normal looking intestine and the grossly inflamed
and diseased segments of intestine [33]. MAP antigens
have appeared to dominate the immunological responses
of intestinal CD4 T cell lines from patients with CD [40].
Mannans released by MAP inhibit intracellular killing of
internalised bacteria [41].Gut Pathogens 2009, 1:15 http://www.gutpathogens.com/content/1/1/15
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The MAP infection causes a primary microscopic inflam-
mation accompanied by a specific immune dysregulation
and enteric neuropathy [33]. Mucosal integrity and other
critical functions of the intestine are impaired. The visible
segments of gross inflammatory disease result from the
perturbed neuroimmune response to the secondary pene-
tration into the gut wall of gut flora containing both nor-
mal intestinal bacteria and those which have undergone
transformations leading to a more invasive phenotype
like AIEC. It is important to note that genomic loci in the
host conferring genetic susceptibility to Crohn's disease
have the potential to operate at the levels of both primary
and secondary pathogens. The entry of food residues into
the gut wall contributes an allergic component to the
inflammatory mess. Although MAP has been found in
intestinal granulomas in humans [42], the presence or
absence of these and other features of the variable his-
topathological picture of CD are principally determined
by the large scale response to the secondary co-pathogens
including especially other granulomatous species like M.
avium subspecies avium which are frequently recovered in
culture from CD tissues [38]. Thus the three lines of con-
temporary research inquiry come together in a two tiered
co-operative pathogenic mechanism.
MAP doomsday
Imagine the collective human enteric microbiome in, say,
a crowded Europe. A vast composite structure made up of
millions of individual highly mobile microbial reservoirs
variably interconnected in time and space and degree. A
dynamic structure possessing an inherent self governing
order and stability not easily displaced. Into this cellular
system is progressively introduced a slowly growing spe-
cific mycobacterial pathogen which has acquired the
genetic machinery necessary to cloak itself with a pre-
dicted fucosylated surface [43] so that it conforms with
the familiar molecular environment particularly of the
host's epithelial cells and mucosal compartment [44]. It
has come from the parallel universe of the collective
enteric microbiome of human food animals and before
that from the soil. It causes a microscopic inflammation
and perturbs the microenvironment of the mucosa and
gut wall. To survive and prosper it minimises its confron-
tation with the human immune system. It causes a varia-
ble immune dysregulation but it also inflames the fine
structure and function of the enteric nervous system.
More than a hundred years go by. Both animal and
human total microbiomes swell with increasing popula-
tion density. The mycobacterial pathogen acquires addi-
tional properties resulting in an evolution in its behaviour
with an increase in pathogenicity and species range. Some
normal inhabitants of the enteric microbiome adapt to
the disturbed intestinal microenvironment and they too
acquire characteristics which make them more invasive.
Chronic enteric disease emerges and spreads particularly
in individuals with an inherited or acquired susceptibility.
Humans responsible for controlling and managing these
diseases, blind to what is really happening are distracted
by detail and dismissive. The required remedial measures
are not designed and applied and the problems get worse.
Left undisturbed, maybe the education in hostility already
received by increasingly aggressive members of the former
normal gut flora will progress to the point where they too
can emerge from background to become primary inde-
pendent pathogens in their own right. When they do so
more new diseases will emerge.
Can anti-MAP treatment heal Crohn's disease?
The answer to this question supported by a correct inter-
pretation of data both from open label studies [45-48]
and the Australian controlled clinical trial is a qualified
yes [49-51]. It can in some people with CD some of the
time. When it does so in 'responders' receiving treatment
with drug combinations including rifabutin and clarithro-
mycin the clinical and pathological improvement can be
dramatic and has been associated with the conversion of
pre-treatment MAP positive tests in blood [52] and gut
mucosa (my own unpublished observations) to negative.
Furthermore, some of the clinical benefit resulting from
treatment of CD with conventional 'immunosuppressive'
agents such as 6-mercaptopurine or methotrexate may
actually be a consequence of their demonstrable direct
anti-MAP action [53-55]. But MAP infections are difficult
to eradicate. The organisms are generally resistant in vivo
to drugs conventionally used in the treatment of tubercu-
losis. Treatment is prone to all the problems of microbial
drug resistance and latency encountered in the manage-
ment of chronic lung disease caused by other members of
the M. Avium Complex.
New clinical trials are needed of anti-MAP treatment in
CD particularly of agents developed for the treatment of
M. tuberculosis which are active against mycobacteria in
the non-replicative state [56] and where the gene encod-
ing the molecular target is shared by MAP. Rich clinical
and commercial rewards are out there for those who do so
successfully.
Conclusion
Recognition and acceptance of the true nature of the
expanding long term threat to human health posed by
widespread exposure to MAP, based upon a perceptive
understanding of the problem and the overwhelming bal-
ance of reliable scientific evidence, is a matter of urgency.
The solutions lie in the identification and incremental
introduction of a range of remedial measures which are
both scientific and regulatory whose effective application
on a global scale requires close international cooperation.Gut Pathogens 2009, 1:15 http://www.gutpathogens.com/content/1/1/15
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